Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyBlue Cross Blue Shield - Nevada Cushing PA | OpenP…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NevadaPolicy N/A

    Prior authorization criteria for Cushing syndrome agents (coverage criteria)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nevada policy alerts

    Know when Blue Cross Blue Shield - Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and clinical criteria for prior authorization of medications used to treat Cushing syndrome and related hypercortisolemia for Anthem/Blue Cross Blue Shield Indiana lines of business; applies to prescribers requesting coverage for listed agents.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization criteria for Cushing syndrome agents (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescriber must complete the PA form, include required attestations and pregnancy test dates where applicable, and fax to the prior authorization center.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9distinct agent-specific PA sections
    18+age & safety attestations

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2prior auth fax lines

    Agent-specific Coverage Criteria

    Isturisa (osilodrostat) - Initial authorization

    Covered when ALL of the following are met

    Isturisa PA criteria: Member is ≥ 18 years of age; Diagnosis of endogenous hypercortisolemia/Cushing's syndrome for whom surgery is not an option or has not been curative; Requested dose is 60 mg/day or less.

    Korlym (mifepristone) - Initial authorization

    Covered when ALL of the following are met

    Korlym PA criteria: Member is ≥ 18 years of age; Diagnosis of hyperglycemia secondary to hypercortisolism in endogenous Cushing's syndrome with type 2 diabetes mellitus or glucose intolerance and failed or is not a candidate for surgery; Prescriber attests member does not have listed contraindications (including specified concomitant medications, endometrial carcinoma, endometrial hyperplasia with atypia, or history of unexplained vaginal bleeding); Member has had a negative pregnancy test within the past 30 days and prescriber has counseled on conception risks and non-hormonal contraception; Requested dose is 1200 mg/day or less.

    Lysodren (mitotane) - Initial authorization

    Covered when ALL of the following are met

    Lysodren PA criteria: Selected diagnosis is Cushing's syndrome or inoperable adrenocortical cancer; Member is ≥ 18 years of age; Member has had a negative pregnancy test in the past 30 days when applicable (documentation included); Requested dose is 12 g/day or less.

    Metopirone (metyrapone) - Initial authorization

    Covered when ALL of the following are met

    Metopirone PA criteria: Selected diagnosis of Cushing's syndrome, pituitary-dependent hypercortisolism, or for diagnostic testing of HPA hormone function; Member is ≥ 18 years of age for treatment indications (diagnostic testing may be exception); Requested dose is 6 g/day or less; Prescriber attests member does not have adrenal cortical insufficiency.

    Recorlev (levoketoconazole) - Initial authorization

    Covered when ALL of the following are met

    Recorlev PA criteria: Member is ≥ 18 years of age; Diagnosis of endogenous hypercortisolemia/Cushing's syndrome for whom surgery is not an option or has not been curative; Requested dose is 1.2 g/day or less; Prescriber attests member does not have any listed contraindications including prior azole-induced liver injury, acute or poorly controlled liver disease, baseline AST/ALT > 3x ULN, baseline QTcF > 470 msec, cirrhosis, concomitant use of QT-prolonging medications or certain CYP3A4/P-gP substrates, extensive metastatic liver disease, history of torsades/ventricular arrhythmia or prolonged QT syndrome, or recurrent symptomatic cholelithiasis.

    Signifor (pasireotide diaspartate) - Initial authorization

    Covered when ALL of the following are met

    Signifor PA criteria: Diagnosis of Cushing's syndrome in members for whom pituitary surgery is not an option or has not been curative; Member is ≥ 18 years of age; Requested dose is 2.4 mg/day or less.

    Signifor LAR (pasireotide pamoate) - Initial authorization

    Covered when ALL of the following are met

    Signifor LAR PA criteria: Selected diagnosis is Cushing's syndrome (pituitary surgery not an option or not curative) or acromegaly with inadequate response to or not a candidate for surgery; Member is ≥ 18 years of age; Requested dose equals 40 mg every 4 weeks for Cushing's syndrome or 60 mg every 4 weeks for acromegaly.

    Use of listed agents is excluded when the specific contraindications called out on the agent section of the prior authorization form are present. Examples include the gynecologic and drug-concomitant exclusions for mifepristone (Korlym) — such as endometrial carcinoma, endometrial hyperplasia with atypia, unexplained vaginal bleeding, and concomitant use of certain strong CYP3A substrates or other specified interacting drugs — and the hepatic, QT, and prior-azole–injury exclusions for levoketoconazole (Recorlev) — including prior azole-induced liver injury, acute or poorly controlled liver disease, baseline AST/ALT >3× ULN, baseline QTcF >470 msec, cirrhosis, and use of drugs that prolong QT or are sensitive CYP3A4/P-gp substrates. Prescriber attestation that none of the agent-specific contraindications apply is required per the form.

    Requests that do not meet the agent-specific criteria on the prior authorization form will not meet medical necessity. The form requires completion of all sections and documentation (including age and diagnosis fields, required attestations, pregnancy testing where applicable, and the requested dose within the listed limit); incomplete forms or missing required information will be returned per the submission instructions.

    Agent Listing and Dosing Information

    Listed agents (no billing codes provided)mixed
    Isturisa (osilodrostat phosphate)Agent name and PA criteria
    Korlym (mifepristone)Agent name and PA criteria
    Lysodren (mitotane)Agent name and PA criteria
    Metopirone (metyrapone)Agent name and PA criteria
    Recorlev (levoketoconazole)Agent name and PA criteria
    Signifor (pasireotide diaspartate)Agent name and PA criteria
    Signifor LAR (pasireotide pamoate)Agent name and PA criteria
    Isturisa (osilodrostat phosphate)mixed
    Isturisa (osilodrostat phosphate)Agent name and PA criteria
    Korlym (mifepristone)mixed
    Korlym (mifepristone)Agent name and PA criteria
    Lysodren (mitotane)mixed
    Lysodren (mitotane)Agent name and PA criteria
    Metopirone (metyrapone)mixed
    Metopirone (metyrapirone)Agent name and PA criteria
    Recorlev (levoketoconazole)mixed
    Recorlev (levoketoconazole)Agent name and PA criteria
    Signifor (pasireotide diaspartate)mixed
    Signifor (pasireotide diaspartate)Agent name and PA criteria
    Signifor LAR (pasireotide pamoate)mixed
    Signifor LAR (pasireotide pamoate)Agent name and PA criteria
    Agent dose limits
    Isturisa (osilodrostat)Maximum requested dose 60 mg/day.
    Korlym (mifepristone)Maximum requested dose 1200 mg/day.
    Lysodren (mitotane)Maximum requested dose 12 g/day.
    Metopirone (metyrapone)Maximum requested dose 6 g/day.
    Recorlev (levoketoconazole)Maximum requested dose 1.2 g/day.
    Signifor (pasireotide diaspartate)Maximum requested dose 2.4 mg/day.
    Signifor LAR (pasireotide pamoate)Requested dose must match indication: 40 mg every 4 weeks for Cushing's or 60 mg every 4 weeks for acromegaly.

    Prior Authorization Requirements and Submission Instructions

    Prior Authorization

    Isturisa (osilodrostat) PA requirements

    Prior authorization required. Member must be ≥18 years old, have a diagnosis of endogenous hypercortisolemia/Cushing's syndrome for whom surgery is not an option or has not been curative, and the requested dose must be 60 mg/day or less.

    Prior Authorization

    Korlym (mifepristone) PA requirements

    Prior authorization required. Member must be ≥18 years old with hyperglycemia secondary to hypercortisolism in endogenous Cushing's syndrome (type 2 diabetes mellitus or glucose intolerance) who have failed or are not candidates for surgery; prescriber must attest no listed contraindications, confirm a negative pregnancy test within 30 days, document counseling on conception risks and non-hormonal contraception, and the requested dose must be 1200 mg/day or less.

    Prior Authorization

    Lysodren (mitotane) PA requirements

    Terms and Required Documentation

    Endogenous hypercortisolemia / Cushing's syndrome
    DefinitionEndogenous hypercortisolemia (Cushing's syndrome) is the clinical diagnosis referenced as the indication for multiple listed agents, specifically when pituitary or adrenal surgery is not an option or has not been curative.
    Agents referencing diagnosisIsturisa, Recorlev, Signifor, Signifor LAR, and others list endogenous hypercortisolemia/Cushing's syndrome as the required diagnosis for authorization.
    Surgical contextAuthorization criteria repeatedly require that surgery is not an option or has not been curative when used for treatment indications.
    Negative pregnancy test
    RequirementNegative pregnancy test documented within the past 30 days is required for agents with teratogenic risk (explicitly listed for mifepristone and mitotane).
    Documentation

    Policy Background

    This prior authorization form exists to support coverage of medical therapies for endogenous hypercortisolemia/Cushing's syndrome in clinical scenarios where surgery is not an option or has not been curative. Several agents (for example, Recorlev) explicitly reference use when surgery is not feasible or curative, and the form collects the clinical attestations and safety screening (age, pregnancy testing when applicable, liver and QTc considerations, and drug-interaction checks) necessary to authorize medical management in these non-surgical situations.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization criteria for Cushing syndrome agents (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescriber must complete the PA form, include required attestations and pregnancy test dates where applicable, and fax to the prior authorization center.
    SourceLink
    On This Page
    Agent-specific Coverage CriteriaAgent Listing and Dosing InformationPrior Authorization Requirements and Submission InstructionsTerms and Required DocumentationPolicy Background

    Prior authorization required. Selected diagnosis must be Cushing's syndrome or inoperable adrenocortical cancer, member must be ≥18 years old, provide a negative pregnancy test within 30 days when applicable, and the requested dose must be 12 g/day or less.

    Prior Authorization

    Metopirone (metyrapone) PA requirements

    Prior authorization required. Indication must be Cushing's syndrome, pituitary-dependent hypercortisolism, or for diagnostic HPA testing; member must be ≥18 years old for treatment indications, prescriber must attest the member does not have adrenal cortical insufficiency, and the requested dose must be 6 g/day or less.

    Prior Authorization

    Recorlev (levoketoconazole) PA requirements

    Prior authorization required. Member must be ≥18 years old, have endogenous hypercortisolemia/Cushing's syndrome for whom surgery is not an option or has not been curative, the requested dose must be 1.2 g/day or less, and prescriber must attest that none of the listed hepatic, QT, drug-interaction, or other contraindications are present.

    Prior Authorization

    Signifor (pasireotide diaspartate) PA requirements

    Prior authorization required. Diagnosis must be Cushing's syndrome in members for whom pituitary surgery is not an option or has not been curative; member must be ≥18 years old and the requested dose must be 2.4 mg/day or less.

    Prior Authorization

    Signifor LAR (pasireotide pamoate) PA requirements

    Prior authorization required. Selected diagnosis must be Cushing's syndrome (pituitary surgery not an option or not curative) or acromegaly (inadequate response to or not candidate for surgery); member must be ≥18 years old and the requested dose must match the indication: 40 mg every 4 weeks for Cushing's syndrome or 60 mg every 4 weeks for acromegaly.

    Step Therapy

    No step therapy specified

    No step therapy sequencing or prior medication failure hierarchy is specified on the form; no sequencing of listed agents is required prior to PA consideration.

    Documentation Required

    Required documentation and attestations

    Prescriber must complete all sections of the prior authorization form, include dates and documentation of negative pregnancy tests where required, and sign attestations regarding contraindications when requested.

    Billing Rule

    Submission instructions — fax numbers

    Fax the completed prior authorization form to the Prior Authorization of Benefits Center: 844-864-7860 for retail prior authorizations or 888-209-7838 for medical injectable prior authorizations.

    Denial Risk

    Incomplete form will be returned

    The prescribing provider must complete all sections of the form; incomplete or missing sections will result in the request being returned.

    Denial Risk

    Denial risk for failure to meet agent-specific criteria

    Requests that do not meet agent-specific criteria (including age requirements, specified diagnosis, requested dose limits, prescriber attestations of absence of contraindications, or required negative pregnancy-test documentation) risk denial.

    Form requires date of negative pregnancy test and supporting documentation to be included on prior authorization submission for applicable agents.
    Contraception counselingFor mifepristone, prescriber must counsel on risks of conception and appropriate non-hormonal contraception in addition to the negative test requirement.